Literature DB >> 18657337

Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies.

Takeo Ito1, Genichiro Ishii, Kanji Nagai, Tatsuya Nagano, Masakazu Kojika, Yukinori Murata, Naho Atsumi, Yutaka Nishiwaki, Eishi Miyazaki, Toshihide Kumamoto, Atsushi Ochiai.   

Abstract

The aim of this study was to identify clinicopathological and biological prognostic markers for patients who had undergone complete resection of pathological stage IB squamous cell carcinoma (SqCC) of the lung. A total of 136 consecutive stage IB SqCC patients fulfilled eligibility criteria, and their clinicopathological factors were evaluated. Tissue microarrays were also constracted, and immunohistochemical staining with 24 antibodies was performed. Correlations between clinicopathological factors, antibody immunohistochemical reactions, the patients' overall survival (OS) and relapse-free survival (RFS) were evaluated. The univariate analysis showed that 70-year-old and over elderly group had a shorter OS time and RFS time than the younger group (p=0.0086 and p=0.0091, respectively). The univariate analysis for immunohistochemical staining showed that the podoplanin-negative group had a shorter OS time and RFS time than the podoplanin-positive group (p=0.0106 and p=0.0308, respectively). Multivariate analysis revealed a significant correlation between both the 70-year-old and over elderly group and the podoplanin-negative group and poor outcome (OS, p=0.007 and p=0.008, respectively; RFS, p=0.008 and p=0.024, respectively). The results showed that patient age and a novel biological prognostic marker, podoplanin, are useful for predicting a poor outcome of patients after complete resection of stage IB SqCC of the lung.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657337     DOI: 10.1016/j.lungcan.2008.06.008

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  20 in total

1.  Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

Authors:  Yukinari Kato; Ganesan Vaidyanathan; Mika Kato Kaneko; Kazuhiko Mishima; Nidhi Srivastava; Vidyalakshmi Chandramohan; Charles Pegram; Stephen T Keir; Chien-Tsun Kuan; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2010-10       Impact factor: 2.408

2.  Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer.

Authors:  Oksana Kowalczuk; Jerzy Laudanski; Wojciech Laudanski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Jacek Niklinski
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

Review 3.  Podoplanin: a novel regulator of tumor invasion and metastasis.

Authors:  Qi Dang; Jie Liu; Juan Li; Yuping Sun
Journal:  Med Oncol       Date:  2014-08-21       Impact factor: 3.064

4.  Evaluation of Podoplanin Expression in Hepatocellular Carcinoma Using RNAscope and Immunohistochemistry - A Preliminary Report.

Authors:  Andreea Cioca; Anca Maria Cimpean; Raluca Amalia Ceausu; Valeria Tarlui; Alina Toma; Irina Marin; Marius Raica
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

5.  Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck.

Authors:  Stefan Huttenlocher; Nina D Seibold; Maximilian P Gebhard; Frank Noack; Christoph Thorns; Katrin Hasselbacher; Barbara Wollenberg; Steven E Schild; Dirk Rades
Journal:  Strahlenther Onkol       Date:  2014-06-14       Impact factor: 3.621

6.  Role of podoplanin expression in deciding the invasive potential of ameloblastoma - A retrospective IHC study.

Authors:  Sindhu M Ganvir; Pratima G Khobragade; Swati A Bamane; Ramnivas Kumavat; Amit Dalmia
Journal:  J Oral Biol Craniofac Res       Date:  2016-07-14

7.  Prognostic Value of Podoplanin in Various Tumors.

Authors:  Xiaohang Wang; Xueying Wang; Vladmir Carvalho; Qianqian Wang; Tingting Li; Jinbang Wang; Yang Chen; Chengming Ni; Subo Liu; Jiaxin Zhang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

8.  Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells.

Authors:  Hanako Suzuki; Mitsuho Onimaru; Yoshikazu Yonemitsu; Yoshihiko Maehara; Seiji Nakamura; Katsuo Sueishi
Journal:  Mol Cancer       Date:  2010-10-31       Impact factor: 27.401

Review 9.  Podoplanin - a small glycoprotein with many faces.

Authors:  Maciej Ugorski; Piotr Dziegiel; Jaroslaw Suchanski
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

10.  Cell surface marker profiling of human tracheal basal cells reveals distinct subpopulations, identifies MST1/MSP as a mitogenic signal, and identifies new biomarkers for lung squamous cell carcinomas.

Authors:  Emily Van de Laar; Monica Clifford; Stefan Hasenoeder; Bo Ram Kim; Dennis Wang; Sharon Lee; Josh Paterson; Nancy M Vu; Thomas K Waddell; Shaf Keshavjee; Ming-Sound Tsao; Laurie Ailles; Nadeem Moghal
Journal:  Respir Res       Date:  2014-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.